Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...

--Best two-day stretch since the two days ending Nov. 11, 2020, when it rose 7.35% --Down 15.77% from its all-time closing high of $87.62 on Aug. 30, 2024 --Up 16.18% from 52 weeks ago (Feb. 8, 2024), ...

Pascal Soriot, chief executive of AstraZeneca, denied any rift with the Government over the decision, which it revealed ...

U.S. shares held steady after European equities hit a record high, and gold prices were near an all-time peak as investor ...

Yet GSK is clearly healing from its multiple comorbidities — the worst of which was the (now largely resolved) legal overhang related to heartburn medicine Zantac. Chief executive Emma Walmsley also ...

A pharma industry group asked the FDA to "take action" against a "dangerous" ad Hims & Hers plans to run during the Super Bowl ...

The deal was signed with the Energize programme, a renewable energy purchasing vehicle for pharmeceutical companies.

Earnings per share excluding some items surged to $2.09, Astra said Thursday, higher than the $2.04 estimated by analysts ...

AstraZeneca continued to see strong growth in 2024 on the back of a series of positive trials, as well as a solid pipeline of ...

AstraZeneca on Thursday warned that it could be fined millions of dollars in importation tax fines as Chinese authorities investigate the company’s former China head. | As AstraZeneca faces an ongoing ...

AstraZeneca stock rose early Thursday after the drugmaker beat fourth-quarter earnings views and delivered upbeat guidance.

The boss of AstraZeneca Plc said he does not believe the UK is the worst place to invest, striking a conciliatory tone just ...